ProMIS Neurosciences Inc. (PMN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, ProMIS Neurosciences reported revenue of $0. Net income was -$39.7M, or -$22.61 per diluted share. Operating activities generated -$28.1M of cash, leaving -$28.1M of free cash flow. At fiscal year end, ProMIS Neurosciences held $9.2M in total assets against $10.4M in total liabilities, including $6.1M of cash and equivalents.
Open the full interactive ProMIS Neurosciences financials → Quarterly statements, key ratios, valuation history and price charts.
ProMIS Neurosciences Key Stats
| Share Price | $8.66 |
|---|---|
| Market Cap | $79.2M |
| 52-Week Range | $6.76 – $24.79 |
| Shares Outstanding | 9.1 million (basic, 2026 Q2) |
ProMIS Neurosciences Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$23.4M | -$14.3M | -$16.8M | -$40.2M |
| Pre-Tax Income | -$18.1M | -$13.2M | $2.8M | -$39.7M |
| Income Tax | — | $0 | $0 | — |
| Net Income | -$18.1M | -$13.2M | $2.8M | -$39.7M |
| Diluted EPS | -$60.25 | -$26.75 | $2.75 | -$22.61 |
ProMIS Neurosciences Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.6M | -$10.7M | -$8.2M | -$11.7M |
| Diluted EPS | -$6.00 | -$6.08 | -$1.26 | -$1.28 |
ProMIS Neurosciences Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $5.9M | $12.6M | $13.3M | $6.1M |
| Current Assets | $6.9M | $13.6M | $18.9M | $9.2M |
| Total Assets | $6.9M | $13.6M | $18.9M | $9.2M |
| Current Liabilities | $6.4M | $9.3M | $2.2M | $10.4M |
| Total Liabilities | $8.3M | $9.9M | $2.4M | $10.4M |
| Shareholders' Equity | -$1.3M | $3.8M | $16.5M | -$1.3M |
ProMIS Neurosciences Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$17.0M | -$10.8M | -$27.2M | -$28.1M |
| Cash From Investing | -$1,981 | -$1,349 | -$693 | -$702 |
| Cash From Financing | $6.5M | $17.7M | $27.9M | $20.9M |
| Free Cash Flow | -$17.0M | -$10.8M | — | -$28.1M |
Figures from ProMIS Neurosciences' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full ProMIS Neurosciences financials page for every line item.
ProMIS Neurosciences Company Profile
| Ticker | PMN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Toronto, Ontario, Canada |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001374339 |
Frequently Asked Questions
What was ProMIS Neurosciences' revenue in fiscal 2025?
ProMIS Neurosciences (PMN) reported revenue of $0 for fiscal 2025.
What is ProMIS Neurosciences' annual revenue history?
ProMIS Neurosciences' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was ProMIS Neurosciences' net income in fiscal 2025?
ProMIS Neurosciences reported net income of -$39.7M for fiscal 2025.
What was ProMIS Neurosciences' earnings per share (EPS) in fiscal 2025?
ProMIS Neurosciences' diluted EPS was -$22.61 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did ProMIS Neurosciences generate in fiscal 2025?
ProMIS Neurosciences generated -$28.1M of free cash flow in fiscal 2025.
What was ProMIS Neurosciences' revenue last quarter?
In its most recent reported quarter (2026 Q2), ProMIS Neurosciences reported revenue of $0.
How many shares of ProMIS Neurosciences are outstanding?
ProMIS Neurosciences reported a weighted average of 9.1 million basic shares outstanding in 2026 Q2.
What is ProMIS Neurosciences' market cap?
Based on its latest closing price, ProMIS Neurosciences (PMN) has a market capitalization of about $79.2M.
When does ProMIS Neurosciences' fiscal year end?
ProMIS Neurosciences' fiscal year end, as registered with the SEC, is December 31.
Where is ProMIS Neurosciences headquartered?
ProMIS Neurosciences lists its business address in Toronto, Ontario, Canada in its SEC filings.